Results

MorphoSys AG

08/01/2020 | Press release | Distributed by Public on 07/31/2020 17:47

FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)